- Home
- TALO vs RCKT Comparison
TALO vs RCKT Comparison
Compare TALO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | RCKT |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 534.2M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | TALO | RCKT |
|---|---|---|
| Price | $16.48 | $3.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $69.50 | $29.65 |
| AVG Volume (30 Days) | 2.3M | ★ 3.2M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,780,070,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.63 | $51.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.23 | $2.19 |
| 52 Week High | $17.01 | $8.26 |
Technical Indicators
Market Signals| Indicator | TALO | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 74.30 | 39.55 |
| Support Level | $10.49 | $2.91 |
| Resistance Level | N/A | $4.08 |
| Average True Range (ATR) | 0.58 | 0.38 |
| MACD | 0.26 | -0.11 |
| Stochastic Oscillator | 87.23 | 4.70 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.